Iterative Health, a healthcare technology and clinical research company, closed a $77 mn Series C financing round led by Intrepid Growth Partners and GV, Google Ventures’ investment arm.
EDBI, part of SG Growth Capital, joined the round alongside a large family office. Existing investors, including Insight Partners and Obvious Ventures, also participated.
The company plans to use the funding to expand beyond gastroenterology and hepatology into cardiology and obesity research, while continuing international growth across its clinical trial network.
Clinical trials remain one of the slowest parts of drug development. Research sites often struggle with enrollment targets, staffing pressure, operational fragmentation, and rising protocol complexity.
According to industry figures cited by Iterative Health, more than half of research sites enroll one or fewer patients per study, while nearly 90% of US-based trials fail to hit enrollment targets on schedule.
Those delays carry real financial weight for pharmaceutical companies. They also slow patient access to new therapies.
Iterative Health built its model around site operations rather than sponsor-side workflow software alone.
According to Beinsure analysts, clinical trial infrastructure has become one of the more active healthcare AI categories because pharmaceutical firms increasingly want operational improvements tied directly to enrollment speed and trial completion rates rather than standalone software products with limited workflow integration.
The company embeds clinical research directly into patient care environments and supports sites through centralized operations, staffing, AI tools, and trial execution infrastructure.
Iterative Health’s network now includes more than 100 research sites across North America, Europe, India, and Australia. The company also works with over 40 pharmaceutical, biotech, medical device, and contract research organizations.
Compared with broader industry benchmarks for inflammatory bowel disease trials, the company says its network delivers site activation twice as fast and reduces startup timelines by as much as three months.
Iterative Health also reports patient enrollment rates three times higher than industry averages, with more than two IBD patients randomized each business day across the network.
Jonathan Ng, founder and CEO of Iterative Health, said delays in clinical trials directly affect patients waiting for new therapies. He said the company built its operating model around physician partners and patient care while scaling high-performance trial execution across multiple sites.
The company plans further partnerships with provider organizations as it expands into additional specialties. Existing collaborations include GI Alliance, OneGI, and U.S. Heart & Vascular.
As part of the financing, Ajay Agrawal, co-founder and partner at Intrepid Growth Partners, will join Iterative Health’s board of directors. Anthony Philippakis, general partner at GV, will join as a board observer.
Agrawal said Intrepid invests in growth-stage companies using AI to redesign operational systems and improve productivity at scale. He described Iterative Health’s clinical trial infrastructure as an example of AI tied directly to measurable operational outcomes across pharmaceutical research.
Philippakis said clinical research remains one of the largest bottlenecks in modern drug development. According to him, Iterative Health combines technical expertise and operational depth to accelerate enrollment and help move therapies through trials faster.
The company’s gastroenterology and hepatology network in the US has already reached significant scale.
Iterative Health now wants to extend the same operating model into new therapeutic areas while expanding relationships with provider organizations integrating research into routine patient care.
Healthcare AI startups often struggle when products remain detached from frontline workflows. Iterative Health is betting the opposite approach works better. Build directly inside clinical operations first, then scale the software around it.
